The global market for community acquired bacterial pneumonia (CABP) treatment is expected to experience robust growth over the next decade, according to a recent market analysis. This growth is driven by increasing awareness about CABP, advancements in diagnostic and treatment technologies, and the growing prevalence of respiratory infections.
From 2018 to 2022, the CABP treatment market demonstrated steady growth with a Compound Annual Growth Rate (CAGR) of 3.2%. This growth trajectory resulted in a market size of USD 5 billion by 2023. Looking forward, the market is projected to accelerate further, reaching an estimated valuation of USD 8.38 billion by 2033, with a CAGR of 5.3%.
Take the First Leap towards a Brighter Future with Our Sample Report Now
The rising awareness of CABP and its potential health implications has spurred demand for effective treatment options. Innovations in medical technology, particularly in diagnostics and pharmaceuticals, are enhancing the accuracy of CABP detection and the efficacy of treatments. This has led to improved patient outcomes and increased adoption of advanced therapeutic options.
Additionally, the healthcare sector’s focus on improving patient care and reducing hospital stays has amplified the demand for effective CABP treatments. The market’s expansion is also supported by a growing geriatric population, who are more susceptible to respiratory infections, and the increasing burden of antibiotic resistance, which necessitates the development of new and more potent antibiotics.
The CABP treatment market’s promising growth prospects present substantial opportunities for stakeholders, including pharmaceutical companies, healthcare providers, and investors. As the market continues to evolve, companies are investing heavily in research and development to bring innovative and effective treatments to the market.
Key Takeaways from the Market Study:
- From 2018 to 2022, the Community Acquired Bacterial Pneumonia (CABP) Treatment market grew at a CAGR of 3.2%.
- The global Community Acquired Bacterial Pneumonia (CABP) Treatment market is expected to grow with a 5.3% CAGR during 2023 to 2033.
- As of 2033, the Community Acquired Bacterial Pneumonia (CABP) Treatment Market is expected to reach USD 8.38 Billion.
- According to the FMI analysis, the hospital phamacies segment accounts for the largest market share.
- North America is expected to possess 40% market share for the Community Acquired Bacterial Pneumonia (CABP) Treatment market.
- The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Community Acquired Bacterial Pneumonia (CABP) Treatment.” says an FMI analyst
Achieve New Heights in Business with the Insights Provided In Get Complete Full Report
Market Competition:
Key players in the market include companies such as Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc., Combioxin SA, Takeda, TiGenix along with healthcare providers and technology companies among other global players.
- The U.S. Food and Drug Administration granted approval for Xenleta (lefamulin) to treat adults suffering from community-acquired bacterial pneumonia. This new drug provides an additional treatment option for patients with this serious illness, which can range in severity from mild to severe and affect people of all ages.
- According to the Centers for Disease Control and Prevention, about one million people in the United States are hospitalized with community-acquired pneumonia each year, and approximately 50,000 individuals succumb to the disease. Dr. Ed Cox, Director of FDA’s Office of Antimicrobial Products, stated that the approval of Xenleta is a significant step in facilitating the development of new antibiotics and addressing the treatment of infectious diseases.
Key Segments Profiled in the Community Acquired Bacterial Pneumonia (CABP) Treatment Industry Survey:
Dose Form:
- Solution
- Tablet
Drug Class:
- Pleuromutilin
- Cephalosporin
- Glycylcycline
- Oxazolidinone
- Ketolide
Route of Administration:
- Oral
- Intravenous
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
